Healthcare / BiotechnologyNasdaqCM
$9.22
+0.22 (+2.44%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-15.8M · quality 68.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
33/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$656M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-31.4%
↓Gross Margin
N/A
•Debt/Equity
0.01
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2020–2025 · 5 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.84x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-29.4M · FCF $-24.7M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Net Income | $-29.4M | $-29.4M | $-21.6M | $-15.4M | $-8.2M | $-24.4M | $-1.1M |
| EBITDA | $-29.6M | $-29.6M | $-22.6M | $-16.1M | $-8.2M | — | — |
| EPS | — | — | -0.76 | -0.89 | -0.59 | -6.64 | — |
| Balance Sheet | |||||||
| Debt/Equity | 0.01 | 0.01 | 0.08 | — | — | — | — |
| Current Ratio | 8.76 | 8.76 | — | — | — | — | — |
| Cash Flow | |||||||
| Free Cash Flow | $-24.7M | $-24.7M | $-15.8M | $-11.4M | $-7.4M | $-1.6M | — |
| Returns | |||||||
| ROE | -31.4% | -31.4% | -163.1% | -94.0% | -62.5% | -135.5% | 24.3% |
| Valuation | |||||||
| P/B | 5.21 | 5.21 | 5.02 | 6.60 | 2.47 | — | — |
| Growth & Yield | |||||||
| EPS Growth | — | — | 14.6% | -50.8% | — | — | — |
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+294.0%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.76 → n/d
Residual
+294.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.